메뉴 건너뛰기




Volumn 39, Issue 7, 2013, Pages 784-792

Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications

Author keywords

Metastatic renal cell carcinoma; MRCC; MTOR inhibitors; Oral Intravenous; Pharmacokinetics

Indexed keywords

ALPHA INTERFERON; ANASTROZOLE; EVEROLIMUS; EXEMESTANE; KETOCONAZOLE; LETROZOLE; PLACEBO; SUNITINIB; TEMSIROLIMUS;

EID: 84881543064     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.12.012     Document Type: Review
Times cited : (22)

References (63)
  • 1
    • 42649145828 scopus 로고    scopus 로고
    • Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review
    • Gupta K., Miller J.D., Li J.Z., et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205.
    • (2008) Cancer Treat Rev , vol.34 , pp. 193-205
    • Gupta, K.1    Miller, J.D.2    Li, J.Z.3
  • 2
    • 68549096316 scopus 로고    scopus 로고
    • Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma
    • Kapoor A., Figlin R.A. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009, 115:3618-3630.
    • (2009) Cancer , vol.115 , pp. 3618-3630
    • Kapoor, A.1    Figlin, R.A.2
  • 3
    • 33846224397 scopus 로고    scopus 로고
    • The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol
    • Antonelli A., Cozzoli A., Zani D., et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007, 99:296-300.
    • (2007) BJU Int , vol.99 , pp. 296-300
    • Antonelli, A.1    Cozzoli, A.2    Zani, D.3
  • 4
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 5
    • 33846148701 scopus 로고    scopus 로고
    • For the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B., Eisen T., Stadler W.M., et al. For the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 6
    • 37349080670 scopus 로고    scopus 로고
    • For the AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    • Escudier B., Pluzanska A., Koralewski P., et al. For the AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
    • (2007) Lancet , vol.370 , pp. 2103-2111
    • Escudier, B.1    Pluzanska, A.2    Koralewski, P.3
  • 7
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    • Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3
  • 8
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 9
    • 77956227464 scopus 로고    scopus 로고
    • Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
    • Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
    • (2010) Cancer , vol.116 , pp. 4256-4265
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 10
    • 0034682783 scopus 로고    scopus 로고
    • Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
    • Cockman M.E., Masson N., Mole D.R., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000, 275:25733-25741.
    • (2000) J Biol Chem , vol.275 , pp. 25733-25741
    • Cockman, M.E.1    Masson, N.2    Mole, D.R.3
  • 11
    • 4644363095 scopus 로고    scopus 로고
    • The von Hippel-Lindau tumor suppressor gene and kidney cancer
    • Kaelin W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290S-6295S.
    • (2004) Clin Cancer Res , vol.10
    • Kaelin, W.G.1
  • 12
    • 16644373473 scopus 로고    scopus 로고
    • Role of VHL gene mutation in human cancer
    • Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004.
    • (2004) J Clin Oncol , vol.22 , pp. 4991-5004
    • Kim, W.Y.1    Kaelin, W.G.2
  • 14
    • 61349116156 scopus 로고    scopus 로고
    • EORTC-GU group expert opinion on metastatic renal cell cancer
    • de Reijke T.M., Bellmunt J., van Poppel H., et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009, 45:765-773.
    • (2009) Eur J Cancer , vol.45 , pp. 765-773
    • de Reijke, T.M.1    Bellmunt, J.2    van Poppel, H.3
  • 15
    • 77954326508 scopus 로고    scopus 로고
    • On behalf of the ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    • Escudier B., Kataja V. On behalf of the ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2009, 21(Suppl. 5):v137-v139.
    • (2009) Ann Oncol , vol.21 , Issue.SUPPL. 5
    • Escudier, B.1    Kataja, V.2
  • 16
    • 77955493600 scopus 로고    scopus 로고
    • EAU guidelines on renal cell carcinoma: the 2010 update
    • Ljungberg B., Cowan N., Hanbury D.C., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
    • (2010) Eur Urol , vol.58 , pp. 398-406
    • Ljungberg, B.1    Cowan, N.2    Hanbury, D.C.3
  • 17
    • 84881544648 scopus 로고    scopus 로고
    • Pfizer Inc. Torisel®, Summary of product characteristics, November 2010.
    • Pfizer Inc. Torisel®, Summary of product characteristics, November 2010.
  • 18
    • 84881543936 scopus 로고    scopus 로고
    • Novartis Pharmaceuticals UK Ltd. Afinitor® (everolimus), Summary of product characteristics, May 2010. Available from:
    • Novartis Pharmaceuticals UK Ltd. Afinitor® (everolimus), Summary of product characteristics, May 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf.
  • 19
    • 33746637660 scopus 로고    scopus 로고
    • Current development of mTOR inhibitors as anticancer agents
    • Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
    • (2006) Nat Rev Drug Discov , vol.5 , pp. 671-688
    • Faivre, S.1    Kroemer, G.2    Raymond, E.3
  • 20
    • 0028950217 scopus 로고
    • Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells
    • Sabers C.J., Martin M.M., Brunn G.J., et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995, 270:815-822.
    • (1995) J Biol Chem , vol.270 , pp. 815-822
    • Sabers, C.J.1    Martin, M.M.2    Brunn, G.J.3
  • 21
    • 72849150434 scopus 로고    scopus 로고
    • Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
    • Yuan R., Kay A., Berg W.J., Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009, 2:45.
    • (2009) J Hematol Oncol , vol.2 , pp. 45
    • Yuan, R.1    Kay, A.2    Berg, W.J.3    Lebwohl, D.4
  • 22
    • 84881545414 scopus 로고    scopus 로고
    • Cayman Chemical Company 2012. Available from: Accessed 11 September, 2012.
    • Cayman Chemical Company 2012. Available from: Accessed 11 September, 2012. http://www.caymanchem.com/app/template/Product.vm/catalog/13346.
  • 23
    • 0032930567 scopus 로고    scopus 로고
    • Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats
    • Crowe A., Bruelisauer A., Duerr L., et al. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999, 27:627-632.
    • (1999) Drug Metab Dispos , vol.27 , pp. 627-632
    • Crowe, A.1    Bruelisauer, A.2    Duerr, L.3
  • 24
    • 34250619165 scopus 로고    scopus 로고
    • The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy
    • Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007, 13:3109-3114.
    • (2007) Clin Cancer Res , vol.13 , pp. 3109-3114
    • Abraham, R.T.1    Gibbons, J.J.2
  • 25
    • 9144233506 scopus 로고    scopus 로고
    • Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
    • Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004, 54:252-261.
    • (2004) Cancer Res , vol.54 , pp. 252-261
    • Boulay, A.1    Zumstein-Mecker, S.2    Stephan, C.3
  • 26
    • 45149094232 scopus 로고    scopus 로고
    • Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modelling of preclinical and clinical pharmacokinetic and pharmacodynamic data
    • Tanaka C., O'Reilly T., Kovarik J.M., et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modelling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008, 26:1596-1602.
    • (2008) J Clin Oncol , vol.26 , pp. 1596-1602
    • Tanaka, C.1    O'Reilly, T.2    Kovarik, J.M.3
  • 27
    • 84881547402 scopus 로고    scopus 로고
    • mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals
    • Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, USA, 22-27 October 2007.
    • Boni J, Burns J, Hug B, Sonnichsen D. mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, USA, 22-27 October 2007.
    • Boni, J.1    Burns, J.2    Hug, B.3    Sonnichsen, D.4
  • 28
    • 0041662261 scopus 로고    scopus 로고
    • Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
    • Peralba J.M., DeGraffenried L., Friedrichs W., et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003, 9:2887-2892.
    • (2003) Clin Cancer Res , vol.9 , pp. 2887-2892
    • Peralba, J.M.1    DeGraffenried, L.2    Friedrichs, W.3
  • 29
    • 35348858663 scopus 로고    scopus 로고
    • Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
    • Cho D., Signoretti S., Dabora S., et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007, 5:379-385.
    • (2007) Clin Genitourin Cancer , vol.5 , pp. 379-385
    • Cho, D.1    Signoretti, S.2    Dabora, S.3
  • 30
    • 84881545835 scopus 로고    scopus 로고
    • Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response
    • Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 4-8 June 2010 (Abstract 3091).
    • Nallari AS, Karrison T, Rosner GL, et al. Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 4-8 June 2010 (Abstract 3091).
    • Nallari, A.S.1    Karrison, T.2    Rosner, G.L.3
  • 31
    • 84861768887 scopus 로고    scopus 로고
    • Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus
    • Lee C.K., Marschner I., Simes J., et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 2012, 18:3188-3196.
    • (2012) Clin Cancer Res , vol.18 , pp. 3188-3196
    • Lee, C.K.1    Marschner, I.2    Simes, J.3
  • 32
    • 1542398693 scopus 로고    scopus 로고
    • Randomized phase II study of multiple dose levels of CCI-779, a mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    • Atkins M.B., Hidalgo M., Stadler W.M. Randomized phase II study of multiple dose levels of CCI-779, a mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918.
    • (2004) J Clin Oncol , vol.22 , pp. 909-918
    • Atkins, M.B.1    Hidalgo, M.2    Stadler, W.M.3
  • 33
    • 72049114956 scopus 로고    scopus 로고
    • Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations
    • Boni J.P., Hug B., Leister C., Sonnichsen D. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol 2009, 36(Suppl. 3):S18-S25.
    • (2009) Semin Oncol , vol.36 , Issue.SUPPL. 3
    • Boni, J.P.1    Hug, B.2    Leister, C.3    Sonnichsen, D.4
  • 34
    • 43249086546 scopus 로고    scopus 로고
    • Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    • O'Donnell A., Faivre S., Burris H.A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26:1588-1595.
    • (2008) J Clin Oncol , vol.26 , pp. 1588-1595
    • O'Donnell, A.1    Faivre, S.2    Burris, H.A.3
  • 35
    • 41849112354 scopus 로고    scopus 로고
    • NCCN Task Force Report: oral chemotherapy
    • Weingart S.N., Brown E., Bach P.B., et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw 2008, 6(Suppl. 3):S13-S14.
    • (2008) J Natl Compr Canc Netw , vol.6 , Issue.SUPPL. 3
    • Weingart, S.N.1    Brown, E.2    Bach, P.B.3
  • 36
    • 43249131245 scopus 로고    scopus 로고
    • Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
    • Tabernero J., Rojo F., Calvo E., et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610.
    • (2008) J Clin Oncol , vol.26 , pp. 1603-1610
    • Tabernero, J.1    Rojo, F.2    Calvo, E.3
  • 37
    • 0034746371 scopus 로고    scopus 로고
    • Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine
    • Kovarik J.M., Kahan B.D., Kaplan B., et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001, 69:48-56.
    • (2001) Clin Pharmacol Ther , vol.69 , pp. 48-56
    • Kovarik, J.M.1    Kahan, B.D.2    Kaplan, B.3
  • 39
    • 0036151699 scopus 로고    scopus 로고
    • Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants
    • Kovarik J.M., Hartmann S., Figueiredo J., et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002, 22:154-159.
    • (2002) Pharmacotherapy , vol.22 , pp. 154-159
    • Kovarik, J.M.1    Hartmann, S.2    Figueiredo, J.3
  • 41
    • 35448978367 scopus 로고    scopus 로고
    • Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications
    • Boni J., Leister C., Burns J., et al. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol 2007, 47:1430-1439.
    • (2007) J Clin Pharmacol , vol.47 , pp. 1430-1439
    • Boni, J.1    Leister, C.2    Burns, J.3
  • 42
    • 2942735384 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
    • Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:2336-2347.
    • (2004) J Clin Oncol , vol.22 , pp. 2336-2347
    • Raymond, E.1    Alexandre, J.2    Faivre, S.3
  • 43
    • 44349099754 scopus 로고    scopus 로고
    • Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
    • Boni J.P., Leister C., Burns J., Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008, 98:1797-1802.
    • (2008) Br J Cancer , vol.98 , pp. 1797-1802
    • Boni, J.P.1    Leister, C.2    Burns, J.3    Hug, B.4
  • 44
    • 0033753435 scopus 로고    scopus 로고
    • Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction
    • Westphal K., Weinbrenner A., Zschiesche M., et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000, 68:345-355.
    • (2000) Clin Pharmacol Ther , vol.68 , pp. 345-355
    • Westphal, K.1    Weinbrenner, A.2    Zschiesche, M.3
  • 45
    • 0036014062 scopus 로고    scopus 로고
    • Effect of rifampin on apparent clearance of everolimus
    • Kovarik J.M., Hartmann S., Figueiredo J., et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002, 36:981-985.
    • (2002) Ann Pharmacother , vol.36 , pp. 981-985
    • Kovarik, J.M.1    Hartmann, S.2    Figueiredo, J.3
  • 46
    • 17644399505 scopus 로고    scopus 로고
    • Blood concentrations of everolimus are markedly increased by ketoconazole
    • Kovarik J.M., Beyer D., Bizot M.N., et al. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005, 45:514-518.
    • (2005) J Clin Pharmacol , vol.45 , pp. 514-518
    • Kovarik, J.M.1    Beyer, D.2    Bizot, M.N.3
  • 47
    • 84881557122 scopus 로고    scopus 로고
    • EMEA. European Public Assessment Report: Temsirolimus Scientific Discussion. Available from: [accessed 11.09.12]
    • EMEA. European Public Assessment Report: Temsirolimus Scientific Discussion. Available from: [accessed 11.09.12]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000799/WC500039915.pdf.
  • 48
    • 11344271046 scopus 로고    scopus 로고
    • Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer
    • Boni J.P., Leister C., Bender G., et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005, 77:76-89.
    • (2005) Clin Pharmacol Ther , vol.77 , pp. 76-89
    • Boni, J.P.1    Leister, C.2    Bender, G.3
  • 49
    • 0031017851 scopus 로고    scopus 로고
    • Patient preferences for oral versus intravenous palliative chemotherapy
    • Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15:110-115.
    • (1997) J Clin Oncol , vol.15 , pp. 110-115
    • Liu, G.1    Franssen, E.2    Fitch, M.I.3    Warner, E.4
  • 50
    • 0036901669 scopus 로고    scopus 로고
    • Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp
    • Laplante A., Demeule M., Murphy G.F., Béliveau R. Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp. Transplant Proc 2002, 34:3393-3395.
    • (2002) Transplant Proc , vol.34 , pp. 3393-3395
    • Laplante, A.1    Demeule, M.2    Murphy, G.F.3    Béliveau, R.4
  • 51
    • 26444602978 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between verapamil and everolimus in healthy subjects
    • Kovarik J.M., Beyer D., Bizot M.N., et al. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005, 60:434-437.
    • (2005) Br J Clin Pharmacol , vol.60 , pp. 434-437
    • Kovarik, J.M.1    Beyer, D.2    Bizot, M.N.3
  • 52
    • 32844467779 scopus 로고    scopus 로고
    • Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy
    • Hartmann B., Schmid G., Graeb C., et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int 2005, 68:2593-2598.
    • (2005) Kidney Int , vol.68 , pp. 2593-2598
    • Hartmann, B.1    Schmid, G.2    Graeb, C.3
  • 53
    • 42349113247 scopus 로고    scopus 로고
    • A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis
    • Shor B., Zhang W.G., Toral-Barza L., et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008, 68:2934-2943.
    • (2008) Cancer Res , vol.68 , pp. 2934-2943
    • Shor, B.1    Zhang, W.G.2    Toral-Barza, L.3
  • 54
    • 33646023695 scopus 로고    scopus 로고
    • Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
    • Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
    • (2006) Mol Cell , vol.22 , pp. 159-168
    • Sarbassov, D.D.1    Ali, S.M.2    Sengupta, S.3
  • 55
    • 34547636060 scopus 로고    scopus 로고
    • Correlation of survival with tumor histology, age and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha
    • [abstract 5033]
    • Dutcher J., Szczylik C., Tannir N., et al. Correlation of survival with tumor histology, age and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha. J Clin Oncol 2007, 25(Suppl. 18S). [abstract 5033].
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL. 18S
    • Dutcher, J.1    Szczylik, C.2    Tannir, N.3
  • 56
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    • Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 57
    • 84896738853 scopus 로고    scopus 로고
    • Everolimus and temsirolimus associated pneumonitis in patients with metastatic renal cell cancer: a single-center experience
    • [abstract 401]
    • Cauley D.H., Atkinson B.J., Ng C.S., et al. Everolimus and temsirolimus associated pneumonitis in patients with metastatic renal cell cancer: a single-center experience. J Clin Oncol 2012, 30(Suppl. 5). [abstract 401].
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL. 5
    • Cauley, D.H.1    Atkinson, B.J.2    Ng, C.S.3
  • 58
    • 66649133114 scopus 로고    scopus 로고
    • A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
    • Amato R.J., Jac J., Giessinger S., et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446.
    • (2009) Cancer , vol.115 , pp. 2438-2446
    • Amato, R.J.1    Jac, J.2    Giessinger, S.3
  • 59
    • 79952806004 scopus 로고    scopus 로고
    • Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus
    • Maroto J.P., Hudes G., Dutcher J.P., et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011, 29:1750-1756.
    • (2011) J Clin Oncol , vol.29 , pp. 1750-1756
    • Maroto, J.P.1    Hudes, G.2    Dutcher, J.P.3
  • 60
    • 33750321673 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
    • Hidalgo M., Buckner J.C., Erlichman C., et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006, 12:5755-5763.
    • (2006) Clin Cancer Res , vol.12 , pp. 5755-5763
    • Hidalgo, M.1    Buckner, J.C.2    Erlichman, C.3
  • 61
    • 84862777361 scopus 로고    scopus 로고
    • Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial
    • Porta C., Calvo E., Climent M.A., et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012, 61:826-833.
    • (2012) Eur Urol , vol.61 , pp. 826-833
    • Porta, C.1    Calvo, E.2    Climent, M.A.3
  • 62
    • 79851500081 scopus 로고    scopus 로고
    • Everolimus for advanced pancreatic neuroendocrine tumors
    • Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:514-523.
    • (2011) N Engl J Med , vol.364 , pp. 514-523
    • Yao, J.C.1    Shah, M.H.2    Ito, T.3
  • 63
    • 84881547645 scopus 로고    scopus 로고
    • CHMP Assessment report for everolimus. Available from: [accessed 11.09.12].
    • CHMP Assessment report for everolimus. Available from: [accessed 11.09.12]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001038/WC500022817.pdf.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.